[Edaily Reporter Kwon Oh Seok ] Shaperon Inc.(378800)announced on the 9th that it has received a notice of proposed designation as a company with inadequate disclosure due to a failure to comply with disclosure requirements. This follows the company’s delayed disclosure of topline data from the Phase 2 clinical trial of “HY209 Gel,” which is intended for patients with mild to moderate atopic dermatitis. The deadline for determining whether the designation will be finalized is the 3rd of next month.